Volatile ride for Agile Therapeutics stock price on Friday moving between $1.76 and $2.09
(Updated on Sep 22, 2023)
The Agile Therapeutics stock price gained 1.73% on the last trading day (Friday, 22nd Sep 2023), rising from $1.73 to $1.76. During the last trading day the stock fluctuated 18.75% from a day low at $1.76 to a day high of $2.09. The price has fallen in 7 of the last 10 days and is down by -16.19% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 48 thousand more shares were traded than the day before. In total, 96 thousand shares were bought and sold for approximately $168.32 thousand.
Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.
The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $1.70 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -33.82% during the next 3 months and, with a 90% probability hold a price between $1.13 and $1.53 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.
AGRX Signals & Forecast
A buy signal was issued from a pivot bottom point on Thursday, September 21, 2023, and so far it has risen 1.73%. Further rise is indicated until a new top pivot has been found. Agile Therapeutics has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Agile Therapeutics stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $1.90 and $2.19. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).
Support, Risk & Stop-loss for Agile Therapeutics stock
Agile Therapeutics finds support from accumulated volume at $1.73 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.330 between high and low, or 18.75%. For the last week, the stock has had daily average volatility of 11.65%.
Agile Therapeutics is oversold on RSI14 (20). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.
Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.
Trading Expectations (AGRX) For The Upcoming Trading Day Of Monday 25th
For the upcoming trading day on Monday, 25th we expect Agile Therapeutics to open at $1.87, and during the day (based on 14 day Average True Range), to move between $1.56 and $1.96, which gives a possible trading interval of +/-$0.197 (+/-11.21%) up or down from last closing price. If Agile Therapeutics takes out the full calculated possible swing range there will be an estimated 22.43% move between the lowest and the highest trading price during the day.
Since the stock is closer to the support from accumulated volume at $1.73 (1.70%) than the resistance at $2.09 (18.75%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..
Is Agile Therapeutics stock A Buy?
Agile Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.
Current score: -4.060 Open Broker AccountSell Candidate Upgraded
Predicted Opening Price for Agile Therapeutics of Monday, September 25, 2023
The predicted opening price is based on yesterday's movements between high, low, and closing price.
|Fair opening price September 25, 2023||Current price|
Remember To Visit Our YouTube Channel
Fibonacci Support & Resistance Levels
Accumulated Volume Support & Resistance Levels
Click here for our free guide on how to buy Agile Therapeutics Stock.
About Agile Therapeutics
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to h... AGRX Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.